Neuroscience and precision medicine by Neumora Therapeutics

  • Igor Krasulya
  • 2 hours ago
Q3 2026 financial results and business update issued by Neumora Therapeutics
Neumora Therapeutics has announced its financial results for the third quarter of 2026 and shared an update on its business operations. Further details about the results and the nature of the ...
  • Pavlo Kot
  • Yesterday
Neumora Therapeutics advances NMRA-215 NLRP3 inhibitor in obesity drug development
Neumora Therapeutics has presented new data on NMRA-215, an oral NLRP3 inhibitor in the company pipeline for obesity treatment. The compound is noted for its high brain penetration and is ...
  • Andrey Mastykin
  • 14.08.2026
Joshua Pinto named Neumora Therapeutics CEO as Paul Berns moves to executive chair role
Neumora Therapeutics announced today the appointment of Joshua Pinto, Ph.D., as the new chief executive officer and member of the Board of Directors. The leadership change coincided with the ...
  • Elena Nikulina
  • 08.06.2026
Neumora Therapeutics advances pipeline for brain penetrant therapies in neurodegenerative and neuropsychiatric disease
Neumora Therapeutics is advancing its pipeline with a focus on developing novel brain penetrant therapies for a wide range of neurological conditions. These include neurodegenerative disorders, ...
  • Mikhail Vnuchkov
  • 01.06.2026
Neumora Therapeutics commits to accelerating Alzheimer agitation therapies
Neumora Therapeutics is amplifying its involvement in Alzheimer awareness initiatives, partnering with the Alzheimer Association to support the EndAlz movement. The company emphasized the rising ...